Advertisement
ALNY or IONS or JNJ
Which Stock Would AI Choose? Alnylam Pharmaceuticals (ALNY) vs. Ionis Pharmaceuticals (IONS) vs. Johnson & Johnson (JNJ) Stock Comparison
Key Takeaways
- ALNY leads with robust 2025 revenue growth of 81% to $2.99B, driven by TTR franchise, but YTD down ~21% amid valuation pressures.
- IONS shows 1-year gains over 100%, supported by olezarsen priority review and 34% revenue rise to $944M, though recent pullback from highs.
- JNJ offers stability with YTD +18%, $582B market cap, 2.15% dividend yield, and consistent oncology/MedTech advancements.
- Biotechs ALNY and IONS exhibit higher volatility and growth potential via RNAi/antisense pipelines, contrasting JNJ's diversified maturity.
- Analyst targets suggest upside: ALNY ~$450 (40%+), IONS ~$89 (25%), JNJ ~$236 (slight downside).
- Recent catalysts include ALNY's Alnylam 2030 strategy, IONS olezarsen PDUFA June 2026, and JNJ oncology approvals.
Introduction
This stock comparison examines ALNY, IONS, and JNJ, three healthcare leaders spanning innovative biotech RNAi/antisense therapies to diversified pharmaceuticals and MedTech. ALNY and IONS focus on RNA-targeted treatments for rare diseases, while JNJ provides broad exposure to oncology, immunology, and devices. Traders seeking high-growth momentum in biotech may favor the former amid pipeline catalysts, whereas long-term investors prioritize JNJ's stability and dividends. Recent market activity highlights relative performance shifts influenced by earnings, regulatory updates, and sector sentiment in the evolving healthcare landscape.
ALNY Overview and Recent Performance
Alnylam Pharmaceuticals (ALNY) pioneers RNAi therapeutics, targeting genetically defined diseases with approved products like AMVUTTRA and ONPATTRO for ATTR amyloidosis. Trading around $313 with a $41.6B market cap, the stock has delivered 30% 1-year returns but declined 21% YTD from 52-week highs near $496. Recent market activity reflects post-earnings volatility after Q4 2025 revenues hit $995M (121% growth) and full-year $2.99B (81% growth), driven by TTR franchise expansion. The "Alnylam 2030" strategy emphasizes TTR leadership and pipeline growth, with Health Canada approval for AMVUTTRA in cardiomyopathy boosting sentiment. Influences include high P/E ~136, analyst targets ~$450, and collaborations like Tenaya for cardiovascular targets, balancing biotech risks with strong guidance of $4.9B-$5.3B 2026 revenues.
IONS Overview and Recent Performance
Ionis Pharmaceuticals (IONS) specializes in antisense technology for RNA-targeted medicines, featuring WAINUA for ATTRv-PN and SPINRAZA for SMA. At ~$71 with $11.8B market cap, shares boast 116% 1-year gains and 10% YTD, though off recent highs near $87. Recent weeks highlighted Q4 2025 revenues of $203M beating estimates, full-year $944M (34% growth), and 2026 guidance $800M-$825M. Key drivers include FDA Priority Review for olezarsen sNDA in severe hypertriglyceridemia (PDUFA June 30, 2026), building on Phase 3 successes reducing triglycerides ~60% and pancreatitis events. Low beta (0.36) underscores resilience, with sentiment lifted by pipeline progress in cardiometabolic and neurology despite ongoing losses.
JNJ Overview and Recent Performance
Johnson & Johnson (JNJ) is a global healthcare giant in pharmaceuticals, MedTech, and consumer health, with strengths in oncology (Darzalex), immunology, and devices. Priced ~$242 with $582B market cap, it offers P/E 22, 2.15% yield, and YTD +18% amid 49% 1-year rise. Recent activity shows steady gains from 52-week highs ~$252, supported by Innovative Medicine and MedTech. Developments include FDA approvals for TECNIS PureSee IOL, promising Erda-iDRS data in bladder cancer, and RYBREVANT expansions in lung cancer. Low beta (0.33) and $94B revenue reflect diversified stability, with oncology surpassing $25B annually influencing positive relative performance versus biotech peers.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases the platform's top-performing AI trading bots, curated from hundreds available that trade thousands of tickers across diverse styles, strategies, timeframes, and performance metrics. These bots employ advanced AI models like Financial Learning Models (FLMs) for pattern recognition, trend prediction, and automated execution, with standout examples delivering annualized returns up to 192%, win rates of 90%+, and profit factors over 2.5 in sectors like aerospace, semiconductors, and cyclicals. Trending selections highlight those best suited to current market conditions, such as volatility in biotech or sector rotations, outperforming benchmarks via multi-agent strategies on ETFs like SOXL or stocks like TSLA. Explore Trending AI Robots to identify bots aligning with your trading approach.
Head-to-Head Comparison
ALNY and IONS share RNA-focused biotech models targeting rare diseases via RNAi and antisense, contrasting JNJ's broad pharma/MedTech diversification. Growth drivers favor biotechs: ALNY's TTR dominance (103% growth) and nucresiran Phase 3 versus IONS' olezarsen catalysts and rare disease launches; JNJ relies on oncology blockbusters and devices. Recent momentum shows JNJ stable (+18% YTD), biotechs volatile (ALNY -21%, IONS +10%). Risks higher for biotechs (no dividends, clinical dependencies) versus JNJ's litigation exposure. Healthcare sector ties all, but ALNY/IONS sensitive to biotech sentiment, JNJ to macro stability. Valuations: biotechs premium P/E (136, N/A) signal growth bets; JNJ reasonable at 22x with yield.
Tickeron AI Verdict
Tickeron’s AI currently favors ALNY due to trend consistency in TTR revenues, 2026 guidance implying ~70% growth, and pipeline catalysts like nucresiran, positioning it strongly amid biotech momentum. IONS follows closely with olezarsen upside, while JNJ excels in stability. Probabilistic edge leans ALNY for relative outperformance based on observable momentum and catalysts.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ALNY’s FA Score shows that 1 FA rating(s) are green whileIONS’s FA Score has 0 green FA rating(s), and JNJ’s FA Score reflects 3 green FA rating(s).
- ALNY’s FA Score: 1 green, 4 red.
- IONS’s FA Score: 0 green, 5 red.
- JNJ’s FA Score: 3 green, 2 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ALNY’s TA Score shows that 2 TA indicator(s) are bullish while IONS’s TA Score has 4 bullish TA indicator(s), and JNJ’s TA Score reflects 3 bullish TA indicator(s).
- ALNY’s TA Score: 2 bullish, 7 bearish.
- IONS’s TA Score: 4 bullish, 4 bearish.
- JNJ’s TA Score: 3 bullish, 6 bearish.
Price Growth
ALNY (@Biotechnology) experienced а -6.62% price change this week, while IONS (@Biotechnology) price change was -0.11% , and JNJ (@Pharmaceuticals: Major) price fluctuated -1.79% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +6.61%. For the same industry, the average monthly price growth was +12.41%, and the average quarterly price growth was +11.94%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +1.75%. For the same industry, the average monthly price growth was +4.38%, and the average quarterly price growth was +7.68%.
Reported Earning Dates
ALNY is expected to report earnings on Apr 30, 2026.
IONS is expected to report earnings on Apr 29, 2026.
JNJ is expected to report earnings on Jul 22, 2026.
Industries' Descriptions
@Biotechnology (+6.61% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
@Pharmaceuticals: Major (+1.75% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| ALNY | IONS | JNJ | |
| Capitalization | 41.5B | 12.4B | 556B |
| EBITDA | 631M | -273.12M | 41.1B |
| Gain YTD | -21.806 | -5.360 | 13.759 |
| P/E Ratio | 133.45 | N/A | 20.91 |
| Revenue | 3.71B | 944M | 94.2B |
| Total Cash | 2.91B | 2.68B | 20.1B |
| Total Debt | 1.28B | 2.07B | 47.9B |
ALNY | IONS | JNJ | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 8 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 94 Overvalued | 100 Overvalued | 26 Undervalued | |
PROFIT vs RISK RATING 1..100 | 53 | 45 | 11 | |
SMR RATING 1..100 | 15 | 98 | 27 | |
PRICE GROWTH RATING 1..100 | 62 | 41 | 46 | |
P/E GROWTH RATING 1..100 | 100 | 76 | 41 | |
SEASONALITY SCORE 1..100 | 50 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
JNJ's Valuation (26) in the Pharmaceuticals Major industry is significantly better than the same rating for ALNY (94) in the Biotechnology industry, and is significantly better than the same rating for IONS (100) in the Biotechnology industry. This means that JNJ's stock grew significantly faster than ALNY’s and significantly faster than IONS’s over the last 12 months.
JNJ's Profit vs Risk Rating (11) in the Pharmaceuticals Major industry is somewhat better than the same rating for IONS (45) in the Biotechnology industry, and is somewhat better than the same rating for ALNY (53) in the Biotechnology industry. This means that JNJ's stock grew somewhat faster than IONS’s and somewhat faster than ALNY’s over the last 12 months.
ALNY's SMR Rating (15) in the Biotechnology industry is in the same range as JNJ (27) in the Pharmaceuticals Major industry, and is significantly better than the same rating for IONS (98) in the Biotechnology industry. This means that ALNY's stock grew similarly to JNJ’s and significantly faster than IONS’s over the last 12 months.
IONS's Price Growth Rating (41) in the Biotechnology industry is in the same range as JNJ (46) in the Pharmaceuticals Major industry, and is in the same range as ALNY (62) in the Biotechnology industry. This means that IONS's stock grew similarly to JNJ’s and similarly to ALNY’s over the last 12 months.
JNJ's P/E Growth Rating (41) in the Pharmaceuticals Major industry is somewhat better than the same rating for IONS (76) in the Biotechnology industry, and is somewhat better than the same rating for ALNY (100) in the Biotechnology industry. This means that JNJ's stock grew somewhat faster than IONS’s and somewhat faster than ALNY’s over the last 12 months.
| ALNY | IONS | JNJ | |
|---|---|---|---|
| RSI ODDS (%) | N/A | 1 day ago 73% | N/A |
| Stochastic ODDS (%) | 4 days ago 63% | 1 day ago 66% | 4 days ago 42% |
| Momentum ODDS (%) | 4 days ago 65% | 1 day ago 71% | 4 days ago 52% |
| MACD ODDS (%) | 4 days ago 72% | 1 day ago 77% | 4 days ago 32% |
| TrendWeek ODDS (%) | 4 days ago 64% | 1 day ago 66% | 4 days ago 40% |
| TrendMonth ODDS (%) | 4 days ago 69% | 1 day ago 74% | 4 days ago 42% |
| Advances ODDS (%) | 7 days ago 76% | 6 days ago 66% | 12 days ago 44% |
| Declines ODDS (%) | 4 days ago 66% | 8 days ago 65% | 4 days ago 41% |
| BollingerBands ODDS (%) | 4 days ago 87% | 1 day ago 67% | 4 days ago 48% |
| Aroon ODDS (%) | 4 days ago 71% | 1 day ago 75% | 4 days ago 38% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| NBIG | 16.40 | 0.31 | +1.93% |
| Leverage Shares 2X Long NBIS Daily ETF | |||
| CCSO | 27.82 | 0.23 | +0.82% |
| Carbon Collective Climate Sol US Eq ETF | |||
| KBE | 64.83 | 0.27 | +0.42% |
| State Street® SPDR® S&P® Bank ETF | |||
| FCPI | 52.58 | -0.24 | -0.46% |
| Fidelity Stocks for Inflation ETF | |||
| CBXJ | 21.41 | -0.13 | -0.59% |
| Calamos Bitcoin 90 Str Alt Prt ETF-Jan | |||
JNJ and
Correlation & Price change
A.I.dvisor indicates that over the last year, JNJ has been loosely correlated with PFE. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if JNJ jumps, then PFE could also see price increases.